



1648  
JPW

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Roland Valdes Jr. et al.      Art Unit : 1648  
Serial No. : 09/503,559      Examiner : U. Winkler  
Filed : February 11, 2000  
Title : DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC & THERAPEUTIC  
COMPOSITIONS AND METHODS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

TRANSMITTAL

The following correspondence relating to this application is enclosed for filing:

1. Supplemental Information Disclosure Statement (1 page);
2. Form PTO-1449 (1 page);
3. Copies of Cited References (5 references);
4. Copy of Supplementary European Search Report (7 pages); and
5. A Return Postcard.

Please date stamp and return the enclosed postcard. Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: July 6, 2004

Ann S. Viksnins  
Ann S. Viksnins  
Reg. No. 37,748

Fish & Richardson P.C., P.A.  
60 South Sixth Street, Suite 3300  
Minneapolis, MN 55402  
(612) 335-5070 telephone  
(612) 288-9696 facsimile

60227621.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

July 6, 2004  
Date of Deposit  
[Signature]  
Signature  
Lisa M. Becker  
Typed or Printed Name of Person Signing Certificate



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Roland Valdes Jr. et al.                      Art Unit : 1648  
Serial No. : 09/503,559                                      Examiner : U. Winkler  
Filed : February 11, 2000  
Title : DIHYDROOUABAIN-LIKE FACTOR AND DIAGNOSTIC & THERAPEUTIC  
COMPOSITIONS AND METHODS

Mail Stop Amendment  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Applicant submits the references listed on the attached form PTO-1449. A copy of a communication from a foreign patent office in a counterpart application is also enclosed.

This statement is being filed before the receipt of a first Office action on the merits.

Please apply any charges or credits to Deposit Account No. 06-1050.

Respectfully submitted,

Date: July 6, 2004

Ann S. Viksnins  
Ann S. Viksnins  
Reg. No. 37,748

Fish & Richardson P.C., P.A.  
60 South Sixth Street  
Suite 3300  
Minneapolis, MN 55402  
Telephone: (612) 335-5070  
Facsimile: (612) 288-9696

60227610.doc

CERTIFICATE OF MAILING BY FIRST CLASS MAIL

I hereby certify under 37 CFR §1.8(a) that this correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

July 6, 2004  
Date of Deposit  
[Signature]  
Signature

Lisa M. Becker  
Typed or Printed Name of Person Signing Certificate

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney's Docket No. 17541-005001	Application No. 09/503,559
<b>Information Disclosure Statement by Applicant</b> (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Roland Valdes Jr. et al.	
		Filing Date February 11, 2000	Group Art Unit 1648

**U.S. Patent Documents**

Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						

**Foreign Patent Documents or Published Foreign Patent Applications**

Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
	AH	GB 949 407	02/12/64	GB				
	AI							
	AJ							
	AK							
	AL							

**Other Documents (include Author, Title, Date, and Place of Publication)**

Examiner Initial	Desig. ID	Document
	AM	Qazzaz et al., "A commercially available standard for dihydroouabain has two chromatographically distinct biologically active components," <u>Clinical Chemistry</u> , 1997, 43:S191
	AN	Qazzaz et al., "Simultaneous isolation of endogenous digoxin-like immunoreactive factor, ouabain-like factor, and deglycosylated congeners from mammalian tissues," <u>Archives of Biochemistry and Biophysics</u> , 1996, 328:193-200
	AO	El-Masri et al., "An antiserum for detection of a newly discovered dihydroouabain-like factor (Dihydro-OLF) isolated from mammals," <u>Clinical Chemistry</u> , 1999, 45:A82
	AP	Qazzaz et al., "A newly discovered lactone-hydrogenated isomer (Dihydro-OLF) of mammalian ouabain-like factor (OLF) differentially inhibits the sodium pump," <u>FASEB J.</u> , 1999, 13:A1470

Examiner Signature	Date Considered
--------------------	-----------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.